260 related articles for article (PubMed ID: 33431157)
41. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.
Saxenian H; Hecht R; Kaddar M; Schmitt S; Ryckman T; Cornejo S
Health Policy Plan; 2015 Mar; 30(2):197-205. PubMed ID: 24510369
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
[TBL] [Abstract][Full Text] [Related]
43. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
44. Influenza vaccine programs for children in low- and middle-income countries: current status and way forward.
Ortiz JR; Neuzil KM
Expert Rev Vaccines; 2019 Jul; 18(7):711-724. PubMed ID: 31226895
[No Abstract] [Full Text] [Related]
45. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
[TBL] [Abstract][Full Text] [Related]
46. Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021-2030.
Sriudomporn S; Watts E; Yoon Sim S; Hutubessy R; Patenaude B
Vaccine X; 2023 Apr; 13():100256. PubMed ID: 36686400
[TBL] [Abstract][Full Text] [Related]
47. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund.
Martin JF; Marshall J
Vaccine; 2003 Jan; 21(7-8):587-92. PubMed ID: 12531322
[TBL] [Abstract][Full Text] [Related]
48. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.
Megiddo I; Colson AR; Nandi A; Chatterjee S; Prinja S; Khera A; Laxminarayan R
Vaccine; 2014 Aug; 32 Suppl 1():A151-61. PubMed ID: 25091670
[TBL] [Abstract][Full Text] [Related]
49. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance.
Lee LA; Franzel L; Atwell J; Datta SD; Friberg IK; Goldie SJ; Reef SE; Schwalbe N; Simons E; Strebel PM; Sweet S; Suraratdecha C; Tam Y; Vynnycky E; Walker N; Walker DG; Hansen PM
Vaccine; 2013 Apr; 31 Suppl 2():B61-72. PubMed ID: 23598494
[TBL] [Abstract][Full Text] [Related]
50. Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
Kraigsley AM; Moore KA; Bolster A; Peters M; Richardson D; Arpey M; Sonnenberger M; McCarron M; Lambach P; Maltezou HC; Bresee JS
Vaccine; 2021 Jun; 39(25):3419-3427. PubMed ID: 33992439
[TBL] [Abstract][Full Text] [Related]
51. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
52. The GAVI Financing Task Force: one model of partner collaboration.
Milstien JB; Kamara L; Lydon P; Mitchell V; Landry S
Vaccine; 2008 Dec; 26(51):6699-705. PubMed ID: 19306508
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
54. Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique.
Haidari LA; Brown ST; Constenla D; Zenkov E; Ferguson M; de Broucker G; Ozawa S; Clark S; Portnoy A; Lee BY
Sex Transm Dis; 2017 Apr; 44(4):222-226. PubMed ID: 28282648
[TBL] [Abstract][Full Text] [Related]
55. Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.
Rodin D; Burger EA; Atun R; Barton M; Gospodarowicz M; Grover S; Hanna TP; Jaffray DA; Knaul FM; Lievens Y; Zubizarreta E; Milosevic M
Lancet Oncol; 2019 Jul; 20(7):915-923. PubMed ID: 31151906
[TBL] [Abstract][Full Text] [Related]
56. Challenges for nationwide vaccine delivery in African countries.
Songane M
Int J Health Econ Manag; 2018 Jun; 18(2):197-219. PubMed ID: 29047019
[TBL] [Abstract][Full Text] [Related]
57. During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved.
Ozawa S; Stack ML; Bishai DM; Mirelman A; Friberg IK; Niessen L; Walker DG; Levine OS
Health Aff (Millwood); 2011 Jun; 30(6):1010-20. PubMed ID: 21653951
[TBL] [Abstract][Full Text] [Related]
58. Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates.
Portnoy A; Vaughan K; Clarke-Deelder E; Suharlim C; Resch SC; Brenzel L; Menzies NA
Pharmacoeconomics; 2020 Sep; 38(9):995-1005. PubMed ID: 32596785
[TBL] [Abstract][Full Text] [Related]
59. Why The Decade Of Vaccines?
Health Aff (Millwood); 2016 Feb; 35(2):188-9. PubMed ID: 26858368
[TBL] [Abstract][Full Text] [Related]
60. Investment case for primary health care in low- and middle-income countries: A case study of Kenya.
Mwai D; Hussein S; Olago A; Kimani M; Njuguna D; Njiraini R; Wangia E; Olwanda E; Mwaura L; Rotich W
PLoS One; 2023; 18(3):e0283156. PubMed ID: 36952482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
